Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Erez's HEM TEST notes 2024 > FL facts > Flashcards

FL facts Flashcards

1
Q

Immunophenotype FL

A

CD19, CD20, CD10 positive

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Translocation FL

A

t(14,18) IgH-bcl2

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

FLIPI

A

age > 60
Hb <12
LDH >ULN
Stage III/IV
> 4 lymph node areas

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Median age FL

A

65

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

BMB involvmment in FL

A

70%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

m7 FLIPI

A

Includes 7 gene mutations in addition to FLIPI- better prognostic ability

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Stage I/II FL %

A

~ 10%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Radiation dose for stage I/II FL

A

24 Gy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Obino vs rituxi for FL

A

GALIUM study
CHOP, CVP, benda - backbone
Anti CD20 also given as maintenance
Obino had better PFS with no OS benefit
7 year PFS 63% vs 55%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

R main in FL

A

PRIMA
Phase III
vs observation
Better PFS but not OS
More toxicities
Median PFS of 10 year
Backbone was R CHOP R CVP or FCM
Not BR

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Tazemetostat for FL

A

EZH2 inhibitor
Phase II
FDA approved in 3rd line FL
not very toxic

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Axi cell in FL

A

ZUMA5
3rd line
phase 2
(included also MZL)
ORR 94%
CR 77%

ZUMA 22
2nd line in POD24 or 3rd line
ongoing

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Tisa cell in FL

A

ELARA trial
3rd line, phase 2
ORR 86%
CR 70%
Bridging Tx was allowed

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

R2 in RR FL

A

AUGMENT
RR FL
vs R
12 cycles
Superior PFS and OS
Median PFS of 40 months

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Mosenutuzumab in FL

A

Bispecific Ab CD20-CD3
Phase II
3rd line
ORR 80%
CR 60%
ICANS/CRS G3 1/2%
8 cycles. 17 if not in CR.
3rd line

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

R vs W&W in low burden FL

A

ARDESHNA trial
R improves PFS
no OS
15-20% in W&W never needed Tx (10 years)
Median time to Tx in W&W- 2.5 years

17
Q

BR vs RCHOP in FL

A

STiL
better PFS
BRIGHT
same PFS

both with less toxicity

18
Q

R2 in ND FL

A

RELEVANCE
compared to R-chemo
non inferior

19
Q

R2-Mosu vs R2 in RR FL

A

CELSTIMO
results pending

20
Q

FLIPI2 vs FLIPI

A

FLIPI2 has BM, node > 6 cm, b2mg
FLIPI has Stage IV, lymph nodes>4, LDH
Both have age>60, Hb<12

21
Q

M7-FLIPI

A

FLIPI + 7 genes

22
Q

R effect on transformation rate in FL

A

Reduces

23
Q

2nd line Tx in FL

A

R^2
R-CHOP
No need for ASCT as consolidation

24
Q

Subtypes of indolent included in STiL study

A

FL
MZL
WM
MCL

Erez's HEM TEST notes 2024 (35 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2025 Bold Learning Solutions. Terms and Conditions